lisaftoclax,acalabrutinib,rituximab
ascentage pharmaceuticals,astrazeneca
['apg-2575', 'acalabrutinib', 'leukemia', 'lymphoma', 'lisaftoclax', 'cll', 'ritux']
later today at 5:15 pm, shares results from a phase 2 study of a new bcl-2 inhibitor in relapsed/refractory #cll. #ash22 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090